Practical Fragments

Practical Fragments

Publication
0 followers

Specialized blog on fragment-based drug discovery – methods, case studies, and compound design – run by industry chemists

Fragments vs the E3 Ligase KLHL12
NewsApr 13, 2026

Fragments vs the E3 Ligase KLHL12

Researchers at Vanderbilt screened 13,824 fragments against the E3 ligase KLHL12, a protein overexpressed in many cancers but absent from heart tissue. The campaign yielded 35 initial hits, with compound 7k emerging as the most potent, displaying sub‑micromolar affinity in...

By Practical Fragments
From Noncovalent Fragment to (Non)covalent Leads Against PLPro
NewsApr 6, 2026

From Noncovalent Fragment to (Non)covalent Leads Against PLPro

Researchers at Vanderbilt have leveraged a protein‑observed NMR fragment screen to revive interest in SARS‑CoV‑2 papain‑like protease (PLPro), an essential viral enzyme with few existing inhibitors. From 13,824 fragments, 77 hits were confirmed, leading to a non‑covalent series that progressed...

By Practical Fragments
Malicious Metals Muddy Fragment-to-Lead Optimization
NewsMar 16, 2026

Malicious Metals Muddy Fragment-to-Lead Optimization

Researchers at the Cleveland Clinic pursued fragment‑based inhibitors of SARS‑CoV‑2 NSP14, a viral exonuclease essential for replication and immune evasion. Initial crystal‑guided merges appeared active in a biochemical assay, prompting optimism about fragment linking. Subsequent resynthesis and rigorous purification revealed...

By Practical Fragments
Selectivity in Cells May Vary
NewsMar 9, 2026

Selectivity in Cells May Vary

The Chemical Probes Portal’s >30‑fold selectivity rule, originally based on cell‑free assays, is challenged by a new open‑access J. Med. Chem. study comparing DiscoverX kinase panels with NanoBRET cellular profiling. Researchers found that most inhibitors appear less potent in living...

By Practical Fragments
Best Practices for Applying HDX-MS to FBLD
NewsMar 2, 2026

Best Practices for Applying HDX-MS to FBLD

A recent open‑access study demonstrates that hydrogen‑deuterium exchange mass spectrometry (HDX‑MS) can reliably map binding sites of extremely weak fragment hits (up to 7 mM KD) against Cyclophilin D. By optimizing protein concentration at 10 µM and testing fragments at 2.5‑10 mM, the...

By Practical Fragments
3D Fragments vs the Histamine H1 Receptor
NewsFeb 16, 2026

3D Fragments vs the Histamine H1 Receptor

Researchers at Vrije Universiteit Amsterdam built an 80‑compound, three‑dimensional fragment library and screened it against the histamine H1 receptor. Only one fragment (1a) showed activity, but iterative optimization yielded the low‑nanomolar antagonist VUF26691 with picomolar cellular potency. The campaign required...

By Practical Fragments
Multivalent Fragments in the Clinic: Muvalaplin
NewsFeb 9, 2026

Multivalent Fragments in the Clinic: Muvalaplin

Researchers at Eli Lilly and Monash University have advanced a multivalent fragment, muvalaplin (LY3473329), to target the Kringle IV‑8 domain of apolipoprotein(a). The trimeric molecule binds three copies of KIV8, achieving picomolar inhibition of Lp(a) assembly in vitro and lowering...

By Practical Fragments
XSAR: Crystallographic SAR From Crude Reactions
NewsFeb 2, 2026

XSAR: Crystallographic SAR From Crude Reactions

Researchers at Diamond Light Source and the University of Oxford introduced xSAR, a quantitative crystallographic SAR approach that converts fragments into Morgan fingerprint bits to calculate Positive and Negative Binding Scores (PBS/NBS). Applying PBS to 957 crude‑reaction fragments recovered 23...

By Practical Fragments
Fragment Merging – and Flipping – on the Leucine Zipper of MITF
NewsJan 26, 2026

Fragment Merging – and Flipping – on the Leucine Zipper of MITF

Researchers at Novartis used 19F NMR to screen the DNA‑binding domain of the microphthalmia‑associated transcription factor (MITF), a leucine‑zipper protein implicated in melanoma. Only nine fragments emerged from the LEF4000 library, reflecting the target’s difficulty. Two series were merged, yielding...

By Practical Fragments
How Best to Assess Molecular Shapeliness?
NewsJan 19, 2026

How Best to Assess Molecular Shapeliness?

The recent open‑access Drug Discovery Today paper evaluates three common metrics for quantifying molecular three‑dimensionality: fraction of sp3‑hybridized carbons (FCsp3), plane of best fit (PBF), and principal moments of inertia (PMI) expressed as ΣNPR. An analysis of half a million...

By Practical Fragments
Review of 2025 Reviews
NewsDec 29, 2025

Review of 2025 Reviews

The Practical Fragments blog celebrated its thousandth post in 2025, highlighting a decade of fragment‑based drug discovery (FBDD) milestones. Key reviews covered fragment‑to‑lead successes, the rise of covalent fragments, AI‑driven cryptic pocket discovery, and extensive bibliometric analysis showing steady global...

By Practical Fragments
GAS41 Revisited: A Chemical Probe
NewsDec 15, 2025

GAS41 Revisited: A Chemical Probe

Researchers at the University of Michigan have refined a fragment‑based series into DLG‑41, a monomeric chemical probe targeting the YEATS domain of GAS41. The probe exhibits ~1 µM affinity by ITC and nanomolar potency in a NanoBRET cellular assay, confirming both...

By Practical Fragments